Stay updated on Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.2 to v3.8.0.
    Difference
    0.0%
    Check dated 2026-11-01T02:15:51.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    A banner was added announcing the NIH website transition and explaining that federal agencies are using “Super Intelligence” in place of “Artificial Intelligence” during the transition.
    Difference
    0.3%
    Check dated 2026-10-25T02:21:16.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision changed from v3.7.1 to v3.7.2.
    Difference
    0.0%
    Check dated 2026-10-18T02:15:11.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer displays an updated site revision number.
    Difference
    0.0%
    Check dated 2026-10-11T03:02:25.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    The record history now shows a new revision entry labeled v3.7.0, indicating the page was updated to that version. The prior v3.6.6 entry is removed from the current diff view.
    Difference
    0.0%
    Check dated 2026-09-20T01:26:25.000Z thumbnail image
  7. Check
    75 days ago
    Change Detected
    Summary
    The record history now includes a new revision entry v3.6.6, replacing v3.6.5, signaling an update to the page’s revision log.
    Difference
    0.0%
    Check dated 2026-08-29T19:39:24.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial page.